NASDAQ:ALDX | Free Cash Flow | Aldeyra Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2013-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$5.11M
2025-12-31-$5.3M
2025-03-31-$12.47M
2024-12-31-$12.04M
2024-03-31-$9.97M
2023-12-31$500,440.00$0.00$500,440.00
2023-03-31-$9.44M$0.00-$9.44M
2022-12-31-$11.23M$0.00-$11.23M
2022-03-31-$12.87M$16,317.00-$12.89M
2021-12-31-$11.58M$0.00-$11.58M
2021-03-31-$13.47M$7,806.00-$13.48M
2020-12-31-$8.32M
2020-03-31-$15.36M
2019-12-31-$11.23M$0.00-$11.23M
2019-03-31-$12.63M$4,925.00-$12.64M
2018-12-31-$7.97M$14,584.00-$7.98M
2018-03-31-$7.95M$139,006.00-$8.09M
2017-12-31-$5.02M$13,167.00-$5.03M
2017-03-31-$4.19M$11,592.00-$4.2M
2016-12-31-$3.91M$0.00-$3.91M
2016-03-31-$4.48M$9,234.00-$4.49M
2015-12-31-$3.01M$0.00-$3.01M
2015-03-31-$1.84M$1,441.00-$1.85M
2014-12-31-$1.61M$7,955.00-$1.61M
2014-03-31-$1.06M
2013-12-31-$601,149.00
2013-03-31-$298,021.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$33.35M
2024-12-31-$43.21M
2023-12-31-$30.33M$0.00-$30.33M
2022-12-31-$56.64M$16,317.00-$56.65M
2021-12-31-$42.56M$7,806.00-$42.56M
2020-12-31-$37.49M
2019-12-31-$44.98M$9,529.00-$44.99M
2018-12-31-$29.86M$262,966.00-$30.12M
2017-12-31-$19.22M$24,759.00-$19.25M
2016-12-31-$15.15M$11,810.00-$15.16M
2015-12-31-$9.31M$86,119.00-$9.4M
2014-12-31-$4.78M$14,062.00-$4.79M
2013-12-31-$1.71M